Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DR2313 是一种选择性,竞争性的和可透过血脑屏障的PARP 抑制剂,对PARP-1和PARP-2的IC50值分别为 0.20 和 0.24 μM。它在体内外均有对缺血性损伤的神经保护作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 297 | 现货 | ||
5 mg | ¥ 486 | 现货 | ||
10 mg | ¥ 816 | 现货 | ||
25 mg | ¥ 1,617 | 现货 | ||
50 mg | ¥ 2,418 | 现货 | ||
100 mg | ¥ 3,548 | 现货 |
产品描述 | DR2313 is a competitive inhibitor of poly(ADP-ribose) polymerase (IC50: 0.20 and 0.24 μM for PARP-1 and PARP-2 respectively). It also has neuroprotective. |
靶点活性 | PARP2:0.24 μM, PARP1:0.20 μM |
体外活性 | DR 2313 decreases neuronal cell death in models of cerebral ischemia in vivo and in vitro. |
体内活性 | In both permanent and transient focal ischemia models in rats, pretreatment with DR2313 (10 mg/kg i.v. bolus and 10 mg/kg/h i.v. infusion for 6 h) significantly reduced the cortical infarct volume.?To determine the therapeutic time window of neuroprotection by DR2313, the effect of post-treatment was examined in transient focal ischemia model and compared with that of a free radical scavenger, MCI-186 (3-methyl-1-phenyl-2-pyrazolone-5-one).?Pretreatment with MCI-186 (3 mg/kg i.v. bolus and 3 mg/kg/h i.v. infusion for 6 h) significantly reduced the infarct volume, whereas the post-treatment failed to show any effects.?In contrast, post-treatment with DR2313 (same regimen) delaying for 2 h after ischemia still prevented the progression of infarction.?These results indicate that DR2313 exerts neuroprotective effects via its potent PARP inhibition, even when the treatment is initiated after ischemia.?Thus, a PARP inhibitor like DR2313 may be more useful in treating acute stroke than a free radical scavenger[1]. |
别名 | DR 2313 |
分子量 | 182.24 |
分子式 | C8H10N2OS |
CAS No. | 284028-90-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 83.3mg/mL
H2O: 9.1mg/mL
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
DR2313 284028-90-6 Chromatin/Epigenetic DNA Damage/DNA Repair PARP polymerase inhibit neuroprotective poly(ADP-ribose) DR-2313 poly ADP ribose polymerase ischemic Inhibitor DR 2313 inhibitor